Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

Bad news for BMS as Keytruda kidney cancer combo approved

Bad news for BMS as Keytruda kidney cancer combo approved The Keytruda duo also cut the risk of death by 46% with those carrying the PD-L1 biomarker – and in 41% of those without. ... This represents a new treatment option for patients with advanced renal cell carcinoma, who will now have access to Keytruda

Tecentriq combo shows promise in triple negative breast cancer

Tecentriq combo shows promise in triple negative breast cancer Roche. Tecentriq's FDA approval in triple negative breast cancer will help it expand in a market dominated by Merck &Co's Keytruda. ... Keynote-552 is investigating Keytruda in combination with different chemotherapy regimens in the neoadjuvant setting

NICE green light for Imfinzi in groundbreaking early lung cancer treatment

NICE green light for Imfinzi in groundbreaking early lung cancer treatment The ruling is great news for the company, as it gives Imfinzi its best chance of competing in the NSCLC market, where MSD’s Keytruda has become the overwhelmingly dominant player. ... Keytruda has marketing authorisation around the world as a

CHMP recommends new Keytruda dosing schedule

CHMP recommends new Keytruda dosing schedule 1 inhibitor that brought in a respectable $6.7bn year, but trailed behind Keytruda and its full year earnings of $7.2bn. ... The PD-1/PD-L1 class is a crowded one and Keytruda’s dominance hasn’t scared off new players from entering the field.

Keytruda adds another NSCLC approval in Europe

Keytruda adds another NSCLC approval in Europe Squamous NSCLC completes first-line dominance. The European Commission has granted MSD's Keytruda approval in another major lung cancer setting. ... With this approval, more patients with non-small cell lung cancer may have the opportunity to benefit

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics